These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 21118551)

  • 1. Medicines information provided by pharmaceutical representatives: a comparative study in Australia and Malaysia.
    Othman N; Vitry AI; Roughead EE; Ismail SB; Omar K
    BMC Public Health; 2010 Nov; 10():743. PubMed ID: 21118551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medicines information in medical journal advertising in Australia, Malaysia and the United States: A comparative cross-sectional study.
    Othman N; Vitry AI; Roughead EE
    South Med Rev; 2010 Feb; 3(1):11-8. PubMed ID: 23093878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Self-regulatory codes of conduct: are they effective in controlling pharmaceutical representatives' presentations to general medical practitioners?
    Roughead EE; Gilbert AL; Harvey KJ
    Int J Health Serv; 1998; 28(2):269-79. PubMed ID: 9595344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Visits by pharmaceutical representatives in general practice as observed by fifth-year medical students.
    Straand J; Cooper J
    Tidsskr Nor Laegeforen; 2018 Jan; 138(1):. PubMed ID: 29313642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doctors' opinions of information provided by Libyan pharmaceutical company representatives.
    Alssageer MA; Kowalski SR
    Libyan J Med; 2012; 7():. PubMed ID: 23205141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of claims, references and the presentation of risk results in medical journal advertising: a comparative study in Australia, Malaysia and the United States.
    Othman N; Vitry AI; Roughead EE
    BMC Public Health; 2010 May; 10():294. PubMed ID: 20509953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What information do physicians receive from pharmaceutical representatives?
    Lexchin J
    Can Fam Physician; 1997 May; 43():941-5. PubMed ID: 9154366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cooperation between physicians and pharmaceutical consultants. A questionnaire study].
    Husby T
    Tidsskr Nor Laegeforen; 1991 Sep; 111(22):2758-60. PubMed ID: 1948870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attitudes of general practitioners in New Zealand to pharmaceutical representatives.
    Thomson AN; Craig BJ; Barham PM
    Br J Gen Pract; 1994 May; 44(382):220-3. PubMed ID: 8204336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dramaturgical study of meetings between general practitioners and representatives of pharmaceutical companies; Commentary: dramaturgical model gives valuable insight.
    Somerset M; Weiss M; Fahey T
    BMJ; 2001 Dec 22-29; 323(7327):1481-4. PubMed ID: 11751364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doctors' Interactions with Pharmaceutical Sales Representatives: Modelling Doctors Prescription Behaviour.
    Faisal A; Ahmad MS; Thurasamy R; Ahmed R
    Community Ment Health J; 2020 Apr; 56(3):456-463. PubMed ID: 31728716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Privately practising nurse practitioners' provision of care subsidised through the Medicare Benefits Schedule and the Pharmaceutical Benefits Scheme in Australia: results from a national survey.
    Currie J; Chiarella M; Buckley T
    Aust Health Rev; 2019 Feb; 43(1):55-61. PubMed ID: 29031290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A survey exploring knowledge and perceptions of general practitioners towards the use of generic medicines in the northern state of Malaysia.
    Chua GN; Hassali MA; Shafie AA; Awaisu A
    Health Policy; 2010 May; 95(2-3):229-35. PubMed ID: 20044165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Quality of pharma rep meetings in general practice].
    Straand J; Christensen IJ
    Tidsskr Nor Laegeforen; 2008 Feb; 128(5):555-7. PubMed ID: 18311197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perception of prescription medicine sample packs among Australian professional, government, industry, and consumer organizations, based on automated textual analysis of one-on-one interviews.
    Kyle GJ; Nissen L; Tett S
    Clin Ther; 2008 Dec; 30(12):2461-73. PubMed ID: 19167604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. General beliefs about medicines among doctors and nurses in out-patient care: a cross-sectional study.
    Mårdby AC; Akerlind I; Hedenrud T
    BMC Fam Pract; 2009 May; 10():35. PubMed ID: 19450260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient awareness and concern regarding pharmaceutical manufacturer interactions with doctors.
    Edwards D; Ballantyne A
    Intern Med J; 2009 Mar; 39(3):191-6. PubMed ID: 19383067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. When is a medicine unwanted, how is it disposed, and how might safe disposal be promoted? Insights from the Australian population.
    Bettington E; Spinks J; Kelly F; Gallardo-Godoy A; Nghiem S; Wheeler AJ
    Aust Health Rev; 2018 Dec; 42(6):709-717. PubMed ID: 29253357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Pharmaceutical Benefits Scheme and implications for paediatric prescribing.
    Sinha Y; Brien JA; Craig JC
    J Paediatr Child Health; 2009 Jun; 45(6):351-7. PubMed ID: 19490409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naturopaths practice behaviour: provision and access to information on complementary and alternative medicines.
    Smith C; Martin K; Hotham E; Semple S; Bloustien G; Rao D
    BMC Complement Altern Med; 2005 Jul; 5():15. PubMed ID: 16004617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.